BR112018016133A2 - aglutinantes de max como moduladores de myc e usos dos mesmos - Google Patents
aglutinantes de max como moduladores de myc e usos dos mesmosInfo
- Publication number
- BR112018016133A2 BR112018016133A2 BR112018016133A BR112018016133A BR112018016133A2 BR 112018016133 A2 BR112018016133 A2 BR 112018016133A2 BR 112018016133 A BR112018016133 A BR 112018016133A BR 112018016133 A BR112018016133 A BR 112018016133A BR 112018016133 A2 BR112018016133 A2 BR 112018016133A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- myc
- binders
- max
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295996P | 2016-02-16 | 2016-02-16 | |
| PCT/US2017/018162 WO2017143059A1 (en) | 2016-02-16 | 2017-02-16 | Max binders as myc modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016133A2 true BR112018016133A2 (pt) | 2019-01-02 |
Family
ID=58191662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016133A BR112018016133A2 (pt) | 2016-02-16 | 2017-02-16 | aglutinantes de max como moduladores de myc e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10106555B2 (https=) |
| EP (1) | EP3416950A1 (https=) |
| JP (1) | JP2019505548A (https=) |
| KR (1) | KR20180107261A (https=) |
| CN (1) | CN109071456A (https=) |
| AU (1) | AU2017221422A1 (https=) |
| BR (1) | BR112018016133A2 (https=) |
| CA (1) | CA3012846A1 (https=) |
| MX (1) | MX2018009913A (https=) |
| RU (1) | RU2018132559A (https=) |
| WO (1) | WO2017143059A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180107261A (ko) | 2016-02-16 | 2018-10-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Myc 조정제로서의 MAX 결합제 및 그의 용도 |
| CA3106118A1 (en) * | 2018-07-09 | 2020-01-16 | The Scripps Research Institute | Improved compounds for myc inhibition |
| CA3160666A1 (en) * | 2019-11-08 | 2021-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitor of apoptosis (iap) protein antagonists |
| CN111274691A (zh) * | 2020-01-16 | 2020-06-12 | 西安交通大学 | 一种分析预测max相材料可形成能力的方法 |
| EP4118081A1 (en) | 2020-03-27 | 2023-01-18 | Landos Biopharma, Inc. | Plxdc2 ligands |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| AU6331099A (en) | 1998-09-30 | 2000-04-17 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| JP4224566B2 (ja) | 2000-12-18 | 2009-02-18 | 株式会社医薬分子設計研究所 | 炎症性サイトカイン産生遊離抑制剤 |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| CA2460541A1 (en) | 2001-09-14 | 2003-04-03 | Helle Birk Olsen | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer |
| US20050042674A9 (en) | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| EP1501509A4 (en) | 2002-04-30 | 2009-07-15 | Merck & Co Inc | ARYL-LINK-ARYL-SUBSTITUTED THIAZOLIDIN-DION- AND OXAZOLIDIN-DION AS SODIUM CHANNEL BLOCKER |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| EP1677794B1 (en) | 2003-09-12 | 2014-12-03 | Elixir Pharmaceuticals, Inc. | Methods of treating disorder |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
| WO2006005683A1 (en) | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| DK1746097T3 (da) | 2005-07-20 | 2010-05-25 | Aventis Pharma Sa | 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| CA2691214A1 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2008012010A1 (en) | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009092764A1 (en) | 2008-01-24 | 2009-07-30 | Ucb Pharma, S.A. | Compounds comprising a cyclobutoxy group |
| US8133695B2 (en) | 2008-02-28 | 2012-03-13 | Life Technologies Corporation | Fluorescence polarization hERG assay |
| CA2743134A1 (en) | 2008-11-10 | 2010-05-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2010058402A1 (en) | 2008-11-20 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Novel anti-biofilm agents |
| US20120040916A1 (en) * | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| JP2013511562A (ja) | 2009-11-24 | 2013-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎阻害化合物 |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| WO2012033149A1 (ja) | 2010-09-10 | 2012-03-15 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体 |
| JPWO2012153780A1 (ja) | 2011-05-11 | 2014-07-31 | 出光興産株式会社 | 新規化合物、有機エレクトロルミネッセンス素子用材料及び有機エレクトロルミネッセンス素子 |
| US9978952B2 (en) | 2011-09-13 | 2018-05-22 | Idemitsu Kosan Co., Ltd. | Fused heterocyclic aromatic derivative, organic electroluminescence element material, and organic electroluminescence element using same |
| JP6653573B2 (ja) | 2012-05-22 | 2020-02-26 | トラスティーズ・オブ・ダートマウス・カレッジ | シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法 |
| SI2941432T1 (en) * | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| BR112015020281B1 (pt) | 2013-02-28 | 2020-04-22 | Sumitomo Chemical Co | composto heterocíclico fundido, agente e método para o controle de pragas |
| US8901164B2 (en) * | 2013-03-07 | 2014-12-02 | University Of Maryland, Baltimore | Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| US9242944B2 (en) | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| EP3082812A4 (en) | 2013-12-11 | 2017-04-26 | The Scripps Research Institute | Small molecule c-myc inhibitors |
| EP3230279A1 (en) | 2014-12-10 | 2017-10-18 | Massachusetts Institute of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| KR20180107261A (ko) | 2016-02-16 | 2018-10-01 | 메사추세츠 인스티튜트 오브 테크놀로지 | Myc 조정제로서의 MAX 결합제 및 그의 용도 |
-
2017
- 2017-02-16 KR KR1020187026354A patent/KR20180107261A/ko not_active Withdrawn
- 2017-02-16 CN CN201780011783.5A patent/CN109071456A/zh active Pending
- 2017-02-16 MX MX2018009913A patent/MX2018009913A/es unknown
- 2017-02-16 BR BR112018016133A patent/BR112018016133A2/pt not_active Application Discontinuation
- 2017-02-16 US US15/435,003 patent/US10106555B2/en active Active
- 2017-02-16 WO PCT/US2017/018162 patent/WO2017143059A1/en not_active Ceased
- 2017-02-16 EP EP17708095.9A patent/EP3416950A1/en not_active Withdrawn
- 2017-02-16 JP JP2018543356A patent/JP2019505548A/ja active Pending
- 2017-02-16 AU AU2017221422A patent/AU2017221422A1/en not_active Abandoned
- 2017-02-16 RU RU2018132559A patent/RU2018132559A/ru not_active Application Discontinuation
- 2017-02-16 CA CA3012846A patent/CA3012846A1/en not_active Abandoned
-
2018
- 2018-10-22 US US16/167,238 patent/US10865213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109071456A (zh) | 2018-12-21 |
| CA3012846A1 (en) | 2017-08-24 |
| EP3416950A1 (en) | 2018-12-26 |
| MX2018009913A (es) | 2018-11-29 |
| RU2018132559A (ru) | 2020-03-17 |
| WO2017143059A1 (en) | 2017-08-24 |
| JP2019505548A (ja) | 2019-02-28 |
| US10106555B2 (en) | 2018-10-23 |
| US20190144466A1 (en) | 2019-05-16 |
| US10865213B2 (en) | 2020-12-15 |
| KR20180107261A (ko) | 2018-10-01 |
| AU2017221422A1 (en) | 2018-08-16 |
| US20170233405A1 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018016133A2 (pt) | aglutinantes de max como moduladores de myc e usos dos mesmos | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| MX2022010703A (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| BR112016002496A2 (pt) | composto de fórmula i, composição farmacêutica, método para inibição de kdm1a, método para tratamento de uma doença mediada por globina, método para atingir um efeito em um paciente, e, método para inibir pelo menos uma função de kdm1a | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| BR112018015413A2 (pt) | inibidores de indoleamina-2,3-dioxigenase (ido) | |
| EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| BR112018076534A2 (pt) | compostos heterocíclicos como imunomoduladores | |
| MX392026B (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| BR112019005305A2 (pt) | compostos espirocíclicos | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| BR112016030730A8 (pt) | composto | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201792341A1 (ru) | Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap) | |
| BR112017016883A2 (pt) | compostos com atividade antitumoral | |
| EA201990399A1 (ru) | Соединения, композиции и их применение | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |